Bridging the Translational Gap in Autoimmune Drug Discovery

Overview

• Inflammatory Bowel Disease (IBD): Explore how research models can be used to evaluate TL1A-targeted therapeutic approaches, with a focus on capturing key inflammatory and fibrotic features of the disease.
• Systemic Lupus Erythematosus (SLE): Examine B-cell depletion strategies and compare different therapeutic approaches using relevant disease models.

• Assess the translational utility of advanced in vitro and in vivo disease models to effectively de-risk candidate selection
• Understand strategies for benchmarking and validating emerging modalities, such as TL1A therapeutics and B cell depleting agents, using robust immunology platforms
• Discover how leveraging integrated, end-to-end CRDMO capabilities can streamline translational research and accelerate timelines from early target identification to IND submission

• R&D and Scientific Leaders: CSOs, Heads of R&D, and VPs/Directors of Immunology seeking to optimize preclinical testing strategies and accelerate autoimmune programs toward IND filing.
• Drug Discovery Scientists: Lead Biologists, Pharmacologists, and Project Investigators looking to leverage reliable in vitro and in vivo disease models for evaluating novel modalities in IBD and SLE.

Speakers

Registration